National Institute of General Medical Sciences; Notice of Closed Meetings, 47538 [2017-21990]
Download as PDF
<![CDATA[
47538
Federal Register / Vol. 82, No. 196 / Thursday, October 12, 2017 / Notices
The
following represents the intellectual
property is to be licensed under the
prospective agreement: HHS Ref. No. E–
181–2016/0, including provisional
patent applications 62/396,613 filed
September 19, 2016 entitled ‘‘Zika Virus
Vaccines’’, and all continuing U.S. and
foreign patents/patent applications for
the technology family, to PaxVax Inc.
All rights in these inventions have
been assigned to the Government of the
United States of America.
The prospective Exclusive Patent
License territory may be worldwide and
the field of use may be limited to:
‘‘Development and use of DNA-based
vaccines expressing virus-like particle
antigens comprising Zika virus
membrane and/or envelope proteins for
prevention of Zika virus infection in
humans.’’
Since 2015, Zika virus (ZIKV)
outbreaks have had a significant effect
on global public health. The mosquitoborne disease, which causes several
congenital abnormalities in the
developing fetus, as well as other
neurological disorders in infected
individuals has no approved vaccine to
treat or prevent infection. To address
this critical need, several approaches are
being explored for a vaccine against
ZIKV infection in priority populations
including women of child-bearing age
and their partners.
Many entities, governmental,
academic, and commercial, are actively
pursuing development of ZIKV vaccines
each using a different approach to
address this public health need. The
U.S. Government is coordinating its
vaccine development response to ZIKV
and has published this plan at https://
www.phe.gov/Preparedness/planning/
Pages/zika-white-paper.aspx.
Vaccine development approaches for
ZIKV include but are not limited to
inactivated virus (dead virus), live
attenuated virus (weakened virus),
recombinant viral vectors (weakened
virus with target genes added), and
subunit (portion of a virus) as well as
mRNA- and DNA-based (gene-targeted).
These various strategies provide
multiple redundancies, expanded
choice, and ensure short and long term
maximal benefits to the public.
The subject invention relates to the
use of nucleic acid molecules encoding
Zika virus (ZIKV) proteins that when
introduced in a cell produces
noninfectious virus-like particles (VLPs)
capable of eliciting a protective immune
response against viral infection. More
specifically, the subject vaccine is a
DNA-based candidate encoding a
polypeptide of a ZIKV membrane and
envelope proteins that when expressed
asabaliauskas on DSKBBXCHB2PROD with NOTICES
SUPPLEMENTARY INFORMATION:
VerDate Sep<11>2014
22:35 Oct 11, 2017
Jkt 244001
results in production of noninfectious
VLPs that generate protective
neutralizing antibodies against ZIKA
infection. The vaccine, which is based
on a similar vaccine developed for the
related West Nile virus, is currently
undergoing clinical trial evaluation. The
subject invention has been advertised in
the Federal Register and published on
12 December 2016.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective Exclusive Patent
License will be royalty bearing and may
be granted unless within thirty (30) days
from the date of this published notice,
the NIAID receives written evidence and
argument that establishes that the grant
of the license would not be consistent
with the requirements of 35 U.S.C. 209
and 37 CFR part 404.
Complete applications for a license in
the prospective field of use that are
timely filed in response to this notice
will be treated as objections to the grant
of the contemplated Exclusive Patent
License. Comments and objections
submitted to this notice will not be
made available for public inspection
and, to the extent permitted by law, will
not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: October 5, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2017–21986 Filed 10–11–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4140–01–P
National Institute of General Medical
Sciences; Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Frm 00093
Fmt 4703
Sfmt 4703
Dated: October 5, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–21990 Filed 10–11–17; 8:45 am]
National Institutes of Health
PO 00000
Panel; Review of Support of Competitive
Research (SCORE) Award Applications.
Date: November 8, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Courtyard by Marriott Chevy Chase,
5520 Wisconsin Avenue, Chevy Chase, MD
20815.
Contact Person: Manas Chattopadhyay,
Ph.D., Scientific Review Officer, Office of
Scientific Review, National Institute of
General Medical Sciences, National Institutes
of Health, Building 45, Room 3An12N, 45
Center Drive, Bethesda, MD 20892, 301–827–
5320, manasc@mail.nih.gov.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel; Review of NIH Pathway to
Independence Award K99/R00 Applications.
Date: November 16, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hilton Garden Inn Bethesda, 7301
Waverly Street, Bethesda, MD 20814.
Contact Person: Robert Horowits, Ph.D.,
Scientific Review Officer, National Institute
of General Medical Sciences, National
Institutes of Health, 45 Center Drive, Room
3An.18, Bethesda, MD 20892–6200, 301–
594–6904, horowitr@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.375, Minority Biomedical
Research Support; 93.821, Cell Biology and
Biophysics Research; 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.862, Genetics and
Developmental Biology Research; 93.88,
Minority Access to Research Careers; 93.96,
Special Minority Initiatives; 93.859,
Biomedical Research and Research Training,
National Institutes of Health, HHS)
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Deafness and
Other Communication Disorders;
Notice of Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Board of Scientific
Counselors, NIDCD.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
E:\FR\FM\12OCN1.SGM
12OCN1
]]>Agencies
[Federal Register Volume 82, Number 196 (Thursday, October 12, 2017)]
[Notices]
[Page 47538]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-21990]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of General Medical Sciences; Notice of Closed
Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of General Medical
Sciences Special Emphasis Panel; Review of Support of Competitive
Research (SCORE) Award Applications.
Date: November 8, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Courtyard by Marriott Chevy Chase, 5520 Wisconsin Avenue,
Chevy Chase, MD 20815.
Contact Person: Manas Chattopadhyay, Ph.D., Scientific Review
Officer, Office of Scientific Review, National Institute of General
Medical Sciences, National Institutes of Health, Building 45, Room
3An12N, 45 Center Drive, Bethesda, MD 20892, 301-827-5320,
manasc@mail.nih.gov.
Name of Committee: National Institute of General Medical
Sciences Special Emphasis Panel; Review of NIH Pathway to
Independence Award K99/R00 Applications.
Date: November 16, 2017.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Hilton Garden Inn Bethesda, 7301 Waverly Street,
Bethesda, MD 20814.
Contact Person: Robert Horowits, Ph.D., Scientific Review
Officer, National Institute of General Medical Sciences, National
Institutes of Health, 45 Center Drive, Room 3An.18, Bethesda, MD
20892-6200, 301-594-6904, horowitr@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.375,
Minority Biomedical Research Support; 93.821, Cell Biology and
Biophysics Research; 93.859, Pharmacology, Physiology, and
Biological Chemistry Research; 93.862, Genetics and Developmental
Biology Research; 93.88, Minority Access to Research Careers; 93.96,
Special Minority Initiatives; 93.859, Biomedical Research and
Research Training, National Institutes of Health, HHS)
Dated: October 5, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-21990 Filed 10-11-17; 8:45 am]
BILLING CODE 4140-01-P
